Yuling Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yuling Zhang has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
Chaozhi Tang
College of Life Science, Henan Normal University, Xinxiang, Henan 453007, China; Department of Neurology, Xinxiang First Peoples Hospital, Xinxiang 453100, China
2 shared publications- Chaozhi Tang
Henan Normal University
1 shared publication - Ganggang Yang
Henan Normal University
1 shared publication Rui Wang
Hangzhou First People's Hospital
1 shared publicationXin Wang
Hangzhou First People's Hospital
1 shared publicationXiying Tan
Hangzhou First People's Hospital
1 shared publication
Latest Publications
- 1 July 2024
- Published by Elsevier in Pathology - Research and Practice
- Vol. 260, 155436
Detailed role of Let-7e in human diseases
- 1 July 2024
- Published by Elsevier in Pathology - Research and Practice
- Vol. 260, 155436
Detailed role of Let-7e in human diseases
- Open Access
Cilostazol may be a better therapeutic agent for acute ischemic stroke because of its efficacy in preventing post-stroke depression
Post-stroke depression (PSD) has more than 1/3 complications in ischemic stroke (IS) patients, but there is still no specific drug that can effectively prevent the occurrence of PSD. Cilostazol, commonly used in the treatment of IS, has been found to rescue cognition impairment in recent years, but whether it has the efficacy in preventing PSD remains uncertain. In this study, a total of 431 acute ischemic stroke (AIS) patients treated with and without cilostazol during 2021-2022 were recruited and followed up for 6 months. At the end of follow-up, we found that AIS patients of cilostazol-treated group had significantly lower National Institutes of Health Stroke Scale (NIHSS) and 24-item Hamilton’s Depression Scale (HAMDS) scores than patients of cilostazol-free group ( p p p p p <0.05). These results suggest that cilostazol is a better therapeutic agent for AIS because it may prevent PSD by decreasing the levels of inflammation in patients.
Open AccessCilostazol may be a better therapeutic agent for acute ischemic stroke because of its efficacy in preventing post-stroke depression
Post-stroke depression (PSD) has more than 1/3 complications in ischemic stroke (IS) patients, but there is still no specific drug that can effectively prevent the occurrence of PSD. Cilostazol, commonly used in the treatment of IS, has been found to rescue cognition impairment in recent years, but whether it has the efficacy in preventing PSD remains uncertain. In this study, a total of 431 acute ischemic stroke (AIS) patients treated with and without cilostazol during 2021-2022 were recruited and followed up for 6 months. At the end of follow-up, we found that AIS patients of cilostazol-treated group had significantly lower National Institutes of Health Stroke Scale (NIHSS) and 24-item Hamilton’s Depression Scale (HAMDS) scores than patients of cilostazol-free group ( p p p p p <0.05). These results suggest that cilostazol is a better therapeutic agent for AIS because it may prevent PSD by decreasing the levels of inflammation in patients.